BriaCell Therapeutics Corp. Operating Income Loss

• BriaCell Therapeutics Corp. showed an increase of +18.4% in Operating Income Loss from 2024 to 2025.
• This data is from BriaCell Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on October 16, 2025.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 5 years of available data (2021 to 2025), BriaCell Therapeutics Corp.'s Operating Income Loss has declined by 290.0%.
• Historical annual values: Fiscal year 2025: -$27.20 million | Fiscal year 2024: -$33.33 million | Fiscal year 2023: -$23.27 million | Fiscal year 2022: -$15.29 million | Fiscal year 2021: -$6.98 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026